title: Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
authors.affiliation: Biology Platform, Sunnybrook Research Institute, Toronto Dept. of Medical Biophysics, University of Toronto, Toronto Sunnybrook Odette Cancer Center, Toronto Dept. of Medicine, University of Toronto, Canada Dept. of Immunology, University of Toronto, Canada spanerd@sri.utoronto.ca.
authors.forename: David E
authors.initials: DE
authors.lastname: Spaner
authors.affiliation: Biology Platform, Sunnybrook Research Institute, Toronto.
authors.forename: Guizhei
authors.initials: G
authors.lastname: Wang
authors.affiliation: Biology Platform, Sunnybrook Research Institute, Toronto.
authors.forename: Lindsay
authors.initials: L
authors.lastname: McCaw
authors.affiliation: Biology Platform, Sunnybrook Research Institute, Toronto.
authors.forename: Yanmei
authors.initials: Y
authors.lastname: Li
authors.affiliation: Toronto East-General Hospital, Canada.
authors.forename: Patricia
authors.initials: P
authors.lastname: Disperati
authors.affiliation: Sunnybrook Odette Cancer Center, Toronto.
authors.forename: Mary-Ann
authors.initials: MA
authors.lastname: Cussen
authors.affiliation: Biology Platform, Sunnybrook Research Institute, Toronto.
authors.forename: Yonghong
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases
keywords: Ibrutinib; Janus Kinases; Kinase inhibitors; Ruxolitinib; STAT3; chronic lymphocytic leukemia; phosphoproteome
references.citation: N Engl J Med. 2012 Mar 1;366(9):787-98
references.pmid: 22375970
references.citation: Blood. 2010 Nov 25;116(22):4569-77
references.pmid: 20716767
references.citation: Blood. 2013 Nov 28;122(23):3843-4
references.pmid: 24288410
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17069-74
references.pmid: 17942672
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Blood. 2015 Jul 23;126(4):471-7
references.pmid: 26065659
references.citation: Blood. 2015 Apr 16;125(16):2497-506
references.pmid: 25700432
references.citation: Lancet Oncol. 2014 Jan;15(1):48-58
references.pmid: 24332241
references.citation: Blood. 2015 Aug 6;126(6):766-78
references.pmid: 26041742
references.citation: Blood. 2012 May 17;119(20):4614-8
references.pmid: 22422826
references.citation: Leukemia. 2012 May;26(5):1144-5
references.pmid: 22064354
references.citation: Leuk Lymphoma. 2011 Dec;52(12):2207-16
references.pmid: 21774745
references.citation: Blood. 2011 Mar 3;117(9):2668-80
references.pmid: 21205928
references.citation: J Chronic Dis. 1961 Apr;13:346-53
references.pmid: 13704181